Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026)

Xilio Therapeutics (XLO) posted Change in Receivables of -$5.0 million for Q1 2026, up 60.0% sequentially from -$12.5 million in Q4 2025.

Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026) Analysis & Trends

Xilio Therapeutics has reported Change in Receivables for 3 years, with the latest figure at -$5.0 million in Q1 2026.

Quarterly Change in Receivables changed N/A year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (changed N/A YoY) and the FY2025 annual result came in at $5.0 million, changed N/A from the prior year.
Change in Receivables improved to -$5.0 million in Q1 2026 per XLO's latest filing, from -$12.5 million in the prior quarter.
Over five years, Change in Receivables peaked at $30.0 million in Q1 2024 and troughed at -$12.5 million in Q4 2025.
A 3-year average of $4.2 million and a median of -$5.0 million in 2026 frame the typical range for Change in Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Xilio Therapeutics	178.33 Mn	42.29 Mn	-	6.00 Mn

Download Data